RSS-Feed abonnieren
DOI: 10.1055/s-0045-1802626
Comparative Analysis of Postoperative Radiotherapy Dose Escalation in Oral Cavity Cancer Patients with Positive Margins: A Propensity Score-Matched Study
Funding None.
Abstract
Introduction This study aimed to determine the impact of postoperative (PO) radiotherapy (RT) dose escalation in oral cavity squamous cell carcinoma (OCSCC) patients with positive margin (PM) in terms of local control (LC), duration of RT interruption, and toxicity in a tertiary care center.
Materials and Methods Patients with OCSCC who were candidates for adjuvant RT were categorized into PM and negative margin (NM) arms depending on the margin status as per the histopathology report retrospectively. PM and NM patients received a total dose of 66 Gy to the site of the PM and 60 Gy for the NM. LC, acute and chronic toxicities, and duration of RT interruption were evaluated.
Results A total of 56 patients were included in the study, of whom 39 had NM and 17 had PM. After propensity score matching, 11 patients were matched in each arm. The mean duration of RT treatment in the PM and NM arms were 49.5 days (standard deviation [SD] = 5.4) and 50.7 days (SD = 10.15) (p = 0.3), with mean interruptions of 3.9 days (SD = 3.9) and 3.8 days (SD = 6.2), respectively (p = 0.39). LC was 72.7% in the PM arm and 81.8% in the NM arm (p = 0.6). Acute and chronic toxicities were comparable between the two arms.
Conclusion Dose escalation to 66 Gy for PM during adjuvant RT for PO OCSCC can be used as an alternative strategy to reresection, especially in patients who have poor performance status, who have negative consent for surgery, and who have more than one adverse prognostic factor with comparable LC and toxicity as in the NM. However, further prospective studies are needed to establish its role as an alternative, which is highly unlikely in modern oncology practice, as PM patients are rarely seen in clinics currently with good surgical oncology practices.
Keywords
oral cavity squamous cell carcinoma - radiotherapy - positive margin - negative margin - postoperativeEthical Approval
The study was performed after obtaining approval from the Institutional Review Board (IM22039) and as per the Declaration of Helsinki guidelines.
Authors' Contribution
R.S. and R.P. collected the data and prepared the Excel sheet. R.S. performed the literature review and prepared the draft manuscript. R.P. presented the idea, guided the work, checked the data, and edited the final manuscript for its scientific content. All the other authors read and approved the final manuscript.
Publikationsverlauf
Eingereicht: 11. Dezember 2024
Angenommen: 08. Januar 2025
Artikel online veröffentlicht:
04. Februar 2025
© 2025. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Montero PH, Patel SG. Cancer of the oral cavity. Surg Oncol Clin N Am 2015; 24 (03) 491-508
- 2 Shah JP. Surgical approaches to the oral cavity primary and neck. Int J Radiat Oncol Biol Phys 2007; 69 (02) S15-S18
- 3 Hermanek P, Wittekind C. The pathologist and the residual tumor (R) classification. Pathol Res Pract 1994; 190 (02) 115-123
- 4 Thomas Robbins K, Triantafyllou A, Suárez C. et al. Surgical margins in head and neck cancer: intra- and postoperative considerations. Auris Nasus Larynx 2019; 46 (01) 10-17
- 5 Luryi AL, Chen MM, Mehra S, Roman SA, Sosa JA, Judson BL. Positive surgical margins in early stage oral cavity cancer: an analysis of 20,602 cases. Otolaryngol Head Neck Surg 2014; 151 (06) 984-990
- 6 Cooper JS, Pajak TF, Forastiere AA. et al; Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350 (19) 1937-1944
- 7 Bernier J, Domenge C, Ozsahin M. et al; European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350 (19) 1945-1952
- 8 Textbook of Radiotherapy | Radiology [Internet]. . [cited December 10, 2024]. Available at: https://pubs.rsna.org/doi/10.1148/88.2.380
- 9 Cooper JS, Zhang Q, Pajak TF. et al. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2012; 84 (05) 1198-1205
- 10 Rosenthal DI, Mohamed ASR, Garden AS. et al. Final report of a prospective randomized trial to evaluate the dose-response relationship for postoperative radiation therapy and pathologic risk groups in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2017; 98 (05) 1002-1011
- 11 Evans M, Beasley M. Target delineation for postoperative treatment of head and neck cancer. Oral Oncol 2018; 86: 288-295
- 12 Eisenhauer EA, Therasse P, Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45 (02) 228-247
- 13 Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31 (05) 1341-1346
- 14 Loganadane G, Kann BH, Park HS. et al. Clinical outcomes of head and neck cancer patients who undergo resection, but forgo adjuvant therapy. Anticancer Res 2019; 39 (09) 4885-4890
- 15 Gokavarapu S, Rao LMC, Mahajan M, Parvataneni N, Raju KVVN, Chander R. Revision of margins under frozen section in oral cancer: a retrospective study of involved margins in pT1 and pT2 oral cancers. Br J Oral Maxillofac Surg 2015; 53 (09) 875-879
- 16 Pfister DG, Spencer S, Adelstein D. et al. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2020; 18 (07) 873-898
- 17 Lorenz FJ, Mahase SS, Miccio J, King TS, Pradhan S, Goyal N. Update on adherence to guidelines for time to initiation of postoperative radiation for head and neck squamous cell carcinoma. Head Neck 2023; 45 (07) 1676-1691
- 18 Graboyes EM, Garrett-Mayer E, Sharma AK, Lentsch EJ, Day TA. Adherence to National Comprehensive Cancer Network guidelines for time to initiation of postoperative radiation therapy for patients with head and neck cancer. Cancer 2017; 123 (14) 2651-2660
- 19 Graboyes EM, Kompelli AR, Neskey DM. et al. Association of treatment delays with survival for patients with head and neck cancer: a systematic review. JAMA Otolaryngol Head Neck Surg 2019; 145 (02) 166-177
- 20 Marcus Jr RB, Million RR, Cassissi NJ. Postoperative irradiation for squamous cell carcinomas of the head and neck: analysis of time-dose factors related to control above the clavicles. Int J Radiat Oncol Biol Phys 1979; 5 (11-12): 1943-1949
- 21 Peters LJ, Goepfert H, Ang KK. et al. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys 1993; 26 (01) 3-11
- 22 Schiff PB, Harrison LB, Strong EW. et al. Impact of the time interval between surgery and postoperative radiation therapy on locoregional control in advanced head and neck cancer. J Surg Oncol 1990; 43 (04) 203-208
- 23 Avkshtol V, Handorf EA, Ridge JA. et al. Examining adjuvant radiation dose in head and neck squamous cell carcinoma. Head Neck 2019; 41 (07) 2133-2142